In 448 patients with newly diagnosed chronic-phase CML, first-line nilotinib vs imatinib with early switch to nilotinib gave more MR4.5 responses at 24 months (65 vs 42 patients; p = 0.02), the first co-primary endpoint.
RCTn = 448
Castagnetti et al. Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint